Department of Anatomy, Howard University College of Medicine, Washington, DC 20059, USA.
J Pharmacol Exp Ther. 2011 Mar;336(3):916-24. doi: 10.1124/jpet.110.173740. Epub 2010 Dec 16.
A small library of anilino enaminones was analyzed for potential anticonvulsant agents. We examined the effects of three anilino enaminones on neuronal activity of output neurons, mitral cells (MC), in an olfactory bulb brain slice preparation using whole-cell patch-clamp recording. These compounds are known to be effective in attenuating pentylenetetrazol-induced convulsions. Among the three compounds tested, 5-methyl-3-(4-trifluoromethoxy-phenylamino)-cyclohex-2-enone (KRS-5Me-4-OCF₃) showed potent inhibition of MC activity with an EC₅₀ of 24.5 μM. It hyperpolarized the membrane potential of MCs accompanied by suppression of spontaneous firing. Neither ionotropic glutamate receptor blockers nor a GABA(B) receptor blocker prevented the KRS-5Me-4-OCF(3)-evoked inhibitory effects. In the presence of GABA(A) receptor antagonists, KRS-5Me-4-OCF(3) completely failed to evoke inhibition of MC spiking activity, suggesting that KRS-5Me-4-OCF₃-induced inhibition may be mediated by direct action on GABA(A) receptors or indirect action through the elevation of tissue GABA levels. Neither vigabatrin (a selective GABA-T inhibitor) nor 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid hydrochloride (NNC-711) (a selective inhibitor of GABA uptake by GABA transporter 1) eliminated the effect of KRS-5ME-4-OCF₃ on neuronal excitability, indicating that the inhibitory effect of the enaminone resulted from direct activation of GABA(A) receptors. The concentration-response curves for GABA are left-shifted by KRS-5Me-4-OCF₃, demonstrating that KRS-5Me-4-OCF₃ enhanced GABA affinity and acted as a positive allosteric modulator of GABA(A) receptors. The effect of KRS-5Me-4-OCF₃ was blocked by applying a benzodiazepine site antagonist, suggesting that KRS-5Me-4-OCF₃ binds at the classic benzodiazepine site to exert its pharmacological action. The results suggest clinical use of enaminones as anticonvulsants in seizures and as a potential anxiolytic in mental disorders.
我们分析了一个小型的苯胺烯胺库,以寻找有潜力的抗惊厥药物。我们使用全细胞膜片钳记录技术,在嗅球脑切片标本中研究了三种苯胺烯胺对输出神经元(即嗅小球细胞)神经元活动的影响。这些化合物在减轻戊四氮诱导的惊厥方面已被证明是有效的。在所测试的三种化合物中,5-甲基-3-(4-三氟甲氧基苯基氨基)-环己-2-烯酮(KRS-5Me-4-OCF₃)对嗅小球细胞的活性表现出强烈的抑制作用,其 EC₅₀为 24.5 μM。它使嗅小球细胞的膜电位超极化,并伴随着自发放电的抑制。离子型谷氨酸受体阻断剂或 GABA(B)受体阻断剂均不能阻止 KRS-5Me-4-OCF₃引起的抑制作用。在 GABA(A)受体拮抗剂存在的情况下,KRS-5Me-4-OCF₃完全不能引起嗅小球细胞放电活动的抑制,这表明 KRS-5Me-4-OCF₃诱导的抑制可能是通过直接作用于 GABA(A)受体或通过提高组织 GABA 水平的间接作用介导的。既不是 vigabatrin(一种选择性 GABA-T 抑制剂),也不是 1,2,5,6-四氢-1-[2-[[(二苯基亚甲基)氨基]氧基]乙基]-3-吡啶羧酸盐酸盐(NNC-711)(一种 GABA 转运蛋白 1 摄取的选择性抑制剂)消除了 KRS-5ME-4-OCF₃对神经元兴奋性的影响,这表明烯胺的抑制作用是由于直接激活 GABA(A)受体。KRS-5Me-4-OCF₃使 GABA 的浓度-反应曲线向左移位,表明 KRS-5Me-4-OCF₃增强了 GABA 的亲和力,并作为 GABA(A)受体的正变构调节剂发挥作用。KRS-5Me-4-OCF₃的作用被应用苯二氮䓬位点拮抗剂所阻断,这表明 KRS-5Me-4-OCF₃结合在经典的苯二氮䓬位点上发挥其药理作用。这些结果表明,烯胺类化合物可作为癫痫发作的抗惊厥药物,并作为精神障碍的潜在抗焦虑药物在临床上使用。